1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Recurrent Hematologic Malignancy: new trials by email Literature Review of Recurrent Hematologic Malignancy trials Research Report on Recurrent Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 |
Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Mastocytosis, Systemic (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Histiocytic Disorders, Malignant (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Mast Cell Activation Disorders (1)
City of Hope Medical Center (1)